...its interesting DTGoody, that two biotech stocks are in the IHub Top 11 'Most Read' and trade in the dollars: PP*M and CT*X. Former has a $242 million dollar Market Cap and the latter has a $290 million Market Cap.
and they both are in Clinical Trials. there is no guarantee that they will pass hope they do they look like good needed drugs and therapy's.
Point is the Market Cap here is less the $10 million......for what would be the newest FDA approved Y-90 Modern day cutting edge cancer treatment .....Clinical Trials on Y-90 were already done in '80's and '90's. yes there are other Y-90 Clinical Trials being done as it is a future branch in medicine for treating cancers -- but ADMD is NOT waiting on a Clinical Trial ...if one reads those two Boards above ...well Clinical Trials take years and years. Here is an excerpt from CT*X DD...:
.... So if Cellceutix can have their first patient enrolled before the end of the summer that would be fast in the world of antibiotic clinical trials. And that would be with many other irons in the fire including a major oncology drug in a phase 1 study and possibly two other phase two trials (Prurisol and Brilacidin-OM) while Tetraphase and Achaogen were just working on one antibiotic each.
The lack of patience of the average investor is amazing. A little patience will be rewarded....
...and that stock is $2.50 .....and we have more immediate huge FDA news pending.
Here with ADMD, we are waiting on a reclassification that will hopefully pass.....and we dont have to wait years....: in fact we are overdue for FDA decision.
IF we get approval, i will post in a whole new light, and compare ADMD to any Biotech and Market Cap out there who also has FDA approved oncology therapies ...especially on the cutting edge.
Cause many of those companies out of Clinical Trial and into actual use of their long developed products -- well their Market Caps are in the billions.
